$369.84
-6.54 (-1.74%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PRAX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
16 interventional · 1 observational · 1 with posted results
Held by 14 tracked-famous managers (Qube Research & Technologies Ltd, MARSHALL WACE, LLP, AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC, Man Group plc, +9 more) · FINRA short interest 11.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 12 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Trial of Vormatrigine in Adult Patients With EpilepsyNCT07287163To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizuresOpen-label · Treatment | Phase 3 | Enrolling by invitation | Drug: vormatrogine | Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure | 700 | 2028-05-31 | in 651 d | 2026-08-03 |
| Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004To evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo | Focal Epilepsy | 300 | Jan 2027 | ≤ 165 d | 2026-08-03 |
| A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo | Developmental and Epileptic Encephalopathy 1 | 160 | Dec 2026 | ≤ 134 d | 2026-08-04 |
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEENon-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: 1mg elsunersen, 0.5mg elsunersen | Epileptic Encephalopathy, SCN2A Encephalopathy | 40 | Dec 2026 | ≤ 134 d | 2026-08-03 |
| A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic EncephalopathyNCT05737784Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses · Procedure: Placebo | SCN2A-DEE, Epilepsy | 60 | 2026-04-01actual | — | 2026-08-03 |
| A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)NCT05818553PART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEsRandomized · Triple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: PRAX-562 | SCN2A Encephalopathy, SCN8A Encephalopathy | 77 | 2025-11-12actual | — | 2026-01-29 |
| Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)NCT06087276Parallel Design: Change from Baseline (CFB) to Week 8 (Day 56) on mADL11 scoreRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: 60 mg ulixacaltamide, Placebo | Essential Tremor | 1,000 | 2025-10-10actual | — | 2026-07-16 |
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresNCT06908356To evaluate the efficacy of PRAX-628 on seizure frequency in adults with FOS or PGTCS currently taking ASMsOpen-label · Treatment | Phase 2 | Recruiting | Drug: 30mg PRAX-628 | Focal Onset Seizure, Primary Generalized Epilepsy | 50 | Jul 2025 | — | 2025-04-03 |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)NCT06999902To evaluate the efficacy of PRAX-628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMsRandomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo | Focal Seizure | 255 | 2026-05-14actual | — | 2026-08-10 |
| A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628NCT06840925To assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsulesRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: PRAX-628 | Healthy | 16 | 2025-06-05actual | — | 2026-08-03 |
| A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic EncephalopathyNCT05407727observationalAssess disease burden and any variation in disease progression over time, as reflected by electrographic seizures, interictal epileptiform discharges (IEDs), and spectral features, as measured on at-home video electroencephalograms (vEEGs) | — | Completed | — | SCN2A-DEE, Epilepsy | 5 | 2023-03-31actual | — | 2024-01-10 |
| A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential TremorNCT05021991Change from baseline to Day 56 on the modified ADLRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: 100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944 | Essential Tremor | 133 | 2023-02-09actual | — | 2024-03-13 |
| A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress DisorderNCT05260541Change from baseline in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score at Day 29Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: No longer developing for this indication | Drug: 60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114 | Post-traumatic Stress Disorder, Post Traumatic Stress Disorder, Stress Disorder, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder | 11 | 2022-08-01actual | — | 2022-12-01 |
| A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderNCT04969510Change from baseline in HAM-D17 total score at Day 15Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo | Major Depressive Disorder | 110 | 2022-07-15actual | — | 2022-08-19 |
| A Clinical Trial of PRAX-114 in Participants With Essential TremorNCT05387642Part A: Incidence and severity of Adverse Events (AE)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor no longer pursuing indication. | Drug: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114 | Essential Tremor | 0 | 2022-06-30actual | — | 2022-11-30 |
| A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15Randomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: PRAX-114, Placebo | Major Depressive Disorder | 216 | 2022-05-05actual | — | 2022-07-21 |
| A Clinical Trial of PRAX-944 in Participants With Essential TremorNCT05021978results2024-03-01Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo | Essential Tremor | 24 | 2022-03-24actual | — | 2024-03-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19